as on November 4, 2025 at 9:48 am IST
Day's Low
0.90%
Downside
52 Week's Low
52 Week's High
4.08%
Downside
84.95%
Upside
as on November 4, 2025 at 9:48 am IST
Market Cap
₹337.70 Cr
Return on Equity (ROE)
4.99
PE Ratio (TTM)
45.71
Return on capital employed (ROCE)
6.37
Industry PE ratio
41.74
Beta (LTM)
0.97
P/B Ratio
2.67
Dividend Yield
0PEG Ratio
8.93
Quarterly Earnings Growth YOY
-22.48
EPS (TTM)
2.22
Sector
Pharmaceuticals
Book Value
29.01
Technical Analysis
Bearish
View Technical Analysis
as on November 4, 2025 at 9:48 am IST
Lyka Labs in the last 5 years
Lowest (-164.66x)
September 10, 2018
Industry (41.74x)
November 3, 2025
Today (45.71x)
November 3, 2025
Highest (56.13x)
July 31, 2025
Today’s Price to Earnings Ratio: 45.71x
Compare market cap, revenue, PE, and other key metrics of Lyka Labs with its industry peers.
Company  | Analyst View | Market Cap(in ₹ Cr)  | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr)  | Yearly Revenue(in ₹ Cr)  | 
|---|---|---|---|---|---|---|
| NA | 337.70 | 95.39% | 0.64 | 7 | 138 | |
| NA | 1,833.78 | 311.74% | 0.71 | 42 | 362 | |
| NA | 2,020.15 | 27.08% | 0.53 | 60 | 759 | |
| BUY | 28,419.00 | 25.06% | 0.68 | 264 | 1,197 | |
| NA | 150.64 | -1.46% | 0.00 | 9 | 118 | 
Search interest for Lyka Labs Ltd Stock has increased by 106% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:106% versus previous 30 day period
Figures in Rupees Crores
Figures in Rupees Crores
Figures in Rupees Crores
View detailed summary of the earnings and dividend history of Lyka Labs.
Lyka Labs Ltd’s net profit fell -35.42% since last year same period to ₹0.93Cr in the Q1 2025-2026. On a quarterly growth basis, Lyka Labs Ltd has generated -47.46% fall in its net profits since last 3-months.
Read More about Earnings ResultsInsights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
FII Holding Up
![]()
Foreign Institutions have increased holdings from 0.16% to 0.17% in Sep 2025 quarter
Against Peers
![]()
In the last 1 year, Divis Laboratories Ltd has given 14.2% return, outperforming this stock by 50.2%
Promoter Holding Unchanged
![]()
Promoters holdings remained unchanged at 58.16% of holdings in Sep 2025 quarter
Against Peers
![]()
In the last 3 years, Torrent Pharmaceuticals Ltd has given 110.7% return, outperforming this stock by 145.2%
Revenue Fall
![]()
Revenue is down for the last 4 quarters, 41.18 Cr → 33.66 Cr (in ₹), with an average decrease of 6.2% per quarter
Retail Holding Down
![]()
Retail Investor have decreased holdings from 41.01% to 41.00% in Sep 2025 quarter
Profit Down
![]()
Netprofit is down for the last 3 quarters, 2.7 Cr → 0.93 Cr (in ₹), with an average decrease of 41.0% per quarter
Price Dip
![]()
In the last 3 months, LYKALABS stock has moved down by -13.3%
| Organisation | Lyka Labs Ltd | 
| Headquarters | Mumbai | 
| Industry | Pharmaceuticals | 
| CEO | KUNAL NARENDRA GANDHI | 
| E-voting on shares | Click here to vote | 
Lyka Labs share price today stands at ₹95.48 as on . Lyka Labs share today touched a day high of ₹95.48 and a low of ₹94.62.
Lyka Labs touched a 52 week high of ₹176.59 and a 52 week low of ₹91.58. Lyka Labs share price today i.e. is trending at ₹95.48, which is -45.93% down from its 52 week high and 4.26% up from its 52 week low.
Lyka Labs market capitalisation is ₹337.70 Cr as on .
To buy Lyka Labs shares, you need to follow these steps:
Lyka Labs trading volume is 138.00 as on . This means that 138.00 shares of Lyka Labs were bought and sold on the stock market during today's trading session.